Clinical Trials
Over 400 Parkinson's Trials Now Recruiting Globally
More than 400 Parkinson's disease clinical trials are actively recruiting patients in 2026 — a decisive turning point for a field long stuck in symptom management. The most substantive disease-modification programs focus on alpha-synuclein clearance, LRRK2 kinase inhibition, and GBA1 substrate reduction — mechanistic approaches grounded in Parkinson's genetics rather than just treating symptoms. Key trials include: prasinezumab (Roche/Prothena) in Phase 2b PADOVA testing anti-alpha-synuclein antibodies in faster-progressing patients; BIIB122/DNL151 (Denali/Biogen) in Phase 2 LIGHTHOUSE trial for LRRK2-mutant Parkinson's; semaglutide in Phase 2 SPARK-PD neuroprotection trial; and AAV-based GDNF gene therapy at multiple Phase 2 centers. *
LRRK2 Inhibitor BIIB122 Advances in Phase 2 LIGHTHOUSE Trial
Denali and Biogen's BIIB122 (also known as DNL151) is advancing through Phase 2 in the LIGHTHOUSE trial (NCT05348785), specifically targeting patients with LRRK2 mutations — the most common known genetic cause of Parkinson's, accounting for up to 40% of cases in Ashkenazi Jewish and North African Berber populations. LRRK2 mutations cause excessive kinase activity that impairs vesicular trafficking and lysosomal function, ultimately damaging dopaminergic neurons. Biomarker endpoints measure CSF and blood LRRK2 substrates as pharmacodynamic measures of target engagement. Results are expected in 2026–2027. Genetic testing for LRRK2 is free for eligible patients through the Michael J. Fox Foundation's Fox Trial Finder. *
Breakthrough Treatments
Blarcamesine Shows Dopaminergic Fiber Regrowth in Advanced PD Model
Anavex Life Sciences presented data at AD/PD 2026 showing that blarcamesine (ANAVEX2-73) completely rescued impaired motor function and promoted fiber regrowth in a new preclinical model combining alpha-synuclein pathology with noradrenergic degeneration — a dual-hit model that more closely mimics Parkinson's disease pathology than previous models. After 6 weeks of blarcamesine treatment, researchers detected significant improvement on motor function tests alongside a biomarker indicating dopaminergic nerve fiber density regrowth in the striatum. The study was presented by Professor Angela Cenci Nilsson of Lund University, Sweden. Blarcamesine works by modulating sigma-1 receptor and muscarinic receptors to restore cellular homeostasis through autophagy — the same mechanism showing promise in Alzheimer's disease. The company previously completed a Phase 2 proof-of-concept study in Parkinson's disease dementia, and this new model supports advancing clinical development in early Parkinson's disease. *
FDA-Approved Compound NALL Targets Multiple Parkinson's Pathways
Northwestern Medicine scientists discovered that N-acetyl-L-leucine (NALL) — already FDA-approved for Niemann-Pick disease type C1 — simultaneously targets multiple molecular pathways implicated in Parkinson's disease, according to a study published in The Journal of Clinical Investigation. NALL works through two key mechanisms: (1) inducing the HTRA1 enzyme to clear pathogenic alpha-synuclein aggregates, and (2) restoring presynaptic dopamine function by increasing parkin levels, which promotes dopamine transporter maturation and improves synaptic vesicle recycling. The researchers used dopaminergic neurons derived from Parkinson's patient stem cells and validated findings in LRRK2-mutant mouse models. "This identifies a potential therapeutic pathway for alpha-synucleinopathies, including Parkinson's disease, and possibly other neurodegenerative disorders," said co-author Dimitri Krainc, MD, PhD, chair of Neurology at Northwestern. *
Lifestyle Interventions
Mediterranean-DASH Diet Shows Promise for Parkinson's Symptom Management
Emerging evidence confirms that sustainable lifestyle changes — increasing physical activity, adopting healthy dietary patterns, and managing stress — can meaningfully impact Parkinson's symptom management and potentially disease progression. The Mediterranean-DASH Intervention for Neurodegeneration (MIND) diet, combining elements of the Mediterranean diet with the DASH diet designed for hypertension, shows particular promise for neurodegenerative disease management. Following a balanced diet improves general well-being and boosts ability to cope with Parkinson's symptoms. Exercise remains the single most evidence-backed intervention for Parkinson's — multiple studies confirm it can improve motor function, balance, and quality of life. Research from 2026 continues to expand understanding of how specific exercise modalities (aerobic, resistance, balance) target different aspects of the disease. Sleep quality and stress management are also increasingly recognized as modifiable factors that influence disease progression. *
Emerging Research
Lundbeck Advances Dopamine D1/D2 Agonist Lu AF28996 into Phase 1b
H. Lundbeck presented Phase 1b data at AD/PD 2026 for Lu AF28996, a novel oral dopamine D1/D2 receptor agonist for people with advanced Parkinson's disease. The trial evaluated safety, tolerability, pharmacokinetics, and early clinical signals in patients with advanced disease experiencing motor fluctuations ("OFF" time) and dyskinesia. Results indicated Lu AF28996 was generally well tolerated with early signals consistent with its proposed mechanism of action, supporting continued clinical development. This represents a new approach for a patient population with significant unmet need — those who have exhausted standard therapies and face persistent mobility issues despite treatment. *
GBA1 Gene Therapy Enters Phase 2 for Most Common Genetic Form
Glucocerebrosidase (GBA1) mutations are the most common genetic risk factor for Parkinson's — present in 5–10% of patients globally and up to 15% in Ashkenazi Jewish populations. GBA1-Parkinson's tends to progress faster with higher rates of cognitive decline. AAV-based gene therapy delivering functional GBA1 directly to the brain is now entering Phase 2 trials, representing one of the most mechanistically grounded approaches for a genetically defined subset of patients. The therapy aims to address the enzyme deficiency at its source rather than managing downstream symptoms. *
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.